Horizon Discovery Group plc Grant of options (0538H)
November 12 2018 - 4:33AM
UK Regulatory
TIDMHZD
RNS Number : 0538H
Horizon Discovery Group plc
12 November 2018
Horizon Discovery Group plc
12 November 2018
Horizon Discovery Group plc
Cambridge, UK, 12 November 2018: Horizon Discovery Group plc
(LSE: HZD) ("Horizon", "the Group" or "the Company"), a global
leader in gene editing and gene modulation technologies, announces
that the following options were granted over the Company's ordinary
shares of 1 pence each ("Ordinary Shares") to its CEO on 9 November
2018 in accordance with the Company's Long Term Incentive Plan:
Director Number of Ordinary Shares Exercise price per share
over which options granted
Terry Pizzie 325,000 GBP2.00
---------------------------- -------------------------
The options will vest as follows:
-- 25% on the third anniversary of the date of grant;
-- 25% on the fourth anniversary of the date of grant; and
-- 50% on the fifth anniversary of the date of grant.
The options granted are equivalent to 0.22 percent of the
Company's existing issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Terry Pizzie
--------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------------- -----------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- -----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
----------------------------------------------------------------
a) Name Horizon Discovery Group plc
--------------------------- -----------------------------------
b) Legal Entity 213800L812B9NI5M3G89
Identifier
--------------------------- -----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
----------------------------------------------------------------
a) Description Ordinary shares of 1 pence each
of the financial
instrument,
type of instrument
GB00BK8FL363
Identification
code
--------------------------- -----------------------------------
b) Nature of Grant of share options
the transaction
--------------------------- -----------------------------------
c) Currency GBP
--------------------------- -----------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------------- ----------------- ----------------
N/A 325,000
-------------------------------------------------- ----------------
e) Aggregated
information
- Aggregated 325,000
volume N/A
- Price N/A
- Aggregated
total
--------------------------- -----------------------------------
f) Date of the 9 November 2018
transaction
--------------------------- -----------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------- -----------------------------------
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR and Transposon) and, following the acquisition
of Dharmacon, Inc., its functional genomics platform comprising
gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for
research and clinical applications that advance human health.
Horizon's platforms and capabilities enable researchers to alter
almost any gene or modulate its function in human or mammalian
cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBGBDBIDBBGID
(END) Dow Jones Newswires
November 12, 2018 05:33 ET (10:33 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024
